
Immunotherapy with nivolumab (Opdivo) after surgery for metastatic bladder cancer significantly reduces the odds for the tumor’s return, a new clinical trial finds. Among 700 patients with urothelial cancer of the bladder or other parts of urinary tract that had spread to muscle, those treated with Opdivo were 30% less likely to have a recurrence… read on > read on >